Adamis Pharmaceuticals (NASDAQ ADMP) traded down $0.05 during trading hours on Tuesday, hitting $4.00.
Wall Street analysts are predicting that Adamis Pharmaceuticl (NASDAQ:ADMP) will report earnings per share of $-0.15 in their quarterly report. On Tuesday, September 12 the stock rating was initiated by Raymond James with "Buy". The company has market cap of $137.75 million. Earnings surprises can have a huge impact on a company's stock price.
Adamis Pharmaceuticals (NASDAQ:ADMP) has been assigned a $14.00 price target by Maxim Group in a research report issued on Tuesday, MarketBeat reports.
Adamis Pharmaceuticl (NASDAQ:ADMP)'s revenue estimates for the current quarter are $4.05 Million according to 2 number of analysts, for the current quarter the company has high revenue estimates of $4.5 Million in contradiction of low revenue estimates of $3.6 Million.
Consequently Adamis Pharmaceuticl (NASDAQ:ADMP)'s weekly and monthly volatility is 12.98%, 8.43% respectively. The brokerage now has a "buy" rating on the specialty pharmaceutical company's stock. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the company. Finally, Zacks Investment Research lowered shares of Adamis Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, November 20th. The stock now has a consensus rating of Hold and a consensus price target of $10.33. 689,000 shares of the stock traded hands, compared to its average volume of 730,169. Its book value per share for the most recent quarter is $1.46 while its price to book ratio for the same period is 3.25, as for as the company's cash per share for the most recent quarter is $0.76, however its price to cash per share ratio for the same period is 6.27. Maxim Group maintained Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) rating on Monday, August 21.
Large investors have recently bought and sold shares of the company. Finally, Sterling Global Strategies LLC grew its position in Adamis Pharmaceuticals by 66.5% in the 2nd quarter. Leisure Capital Management lifted its holdings in Adamis Pharmaceuticals by 7.2% in the 2nd quarter. Advisor Group Inc. now owns 56,001 shares of the specialty pharmaceutical company's stock worth $292,000 after buying an additional 33,591 shares in the last quarter. Leisure Capital Management now owns 145,909 shares of the specialty pharmaceutical company's stock worth $759,000 after purchasing an additional 9,832 shares in the last quarter. EAM Investors LLC now owns 371,732 shares of the specialty pharmaceutical company's stock valued at $1,942,000 after acquiring an additional 136,970 shares in the last quarter. If you are viewing this report on another publication, it was stolen and republished in violation of USA and worldwide trademark & copyright laws. The companyÂ's specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease.